Results 201 to 210 of about 1,341,475 (356)

A Needle‐Like H2S‐Releasing and H2O2 Self‐Replenishing Nanoplatform for Enhanced Chemodynamic Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
The PTA‐SnS2@GOx cascade nanosystem presents a smart paradigm for cancer theranostics, integrating self‐supplied H2S/H2O2‐augmented chemodynamic therapy (CDT) with sensitized immunotherapy. Its needle‐like SnS2 shell enhances tumor‐specific uptake, ensuring biosafety.
Xiaoxiao Sun   +3 more
wiley   +1 more source

WTAP Mediated m6A Modification Stabilizes PDIA3P1 and Promotes Tumor Progression Driven by Histone Lactylation in Esophageal Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
This study reveals a new mechanism by which PDIA3P1 regulates the progression of esophageal squamous cell carcinoma (ESCC). PDIA3P1 upregulates the expression of GLUT1 and HK2, promoting glycolysis and lactate production. Lactate upregulates the lactylation level of histone H4K8 and activates the transcription of target gene BMP7, ultimately ...
Tao Huang   +13 more
wiley   +1 more source

Breast Augmentation Patient Satisfaction in an Appalachian Region. [PDF]

open access: yesCureus
Rahimpour A   +6 more
europepmc   +1 more source

Breast Augmentation in Transwomen: Can We have a Formula?

open access: yesIndian J Plast Surg, 2023
Chatterjee SS, Khanna M, Yadav N.
europepmc   +1 more source

A Prospective, Randomized, Double-Blind, Controlled Trial of Continuous Local Anesthetic Infusion in Cosmetic Breast Augmentation

open access: bronze, 2008
Fereydoun Don Parsa   +5 more
openalex   +1 more source

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer

open access: yesAdvanced Science, EarlyView.
Drug‐tolerant persister (DTP) cells emerge early during EGFR‐TKI treatment, preceding the development of acquired resistance. Elevated DPP4 in DTP cells drives metabolic reprogramming and antioxidant adaptation, promoting cell survival under drug pressure.
Yuanzhou Zhang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy